Andrew Ridder, MD
Neurology · Sioux Falls, SDNPI 1285993253
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,473 of the $96,906 with a category attached, or 76.9%. Neurocrine Biosciences, Inc. accounts for 90.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $27,268 and has fallen 99.1% since, to $234 in 2025. Among neurology clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $510.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$88K
- Livanova USA, Inc.$3K
- Medtronic$2K
- Amneal Pharmaceuticals LLC$1K
- Boston Scientific$1K
- AbbVie$296
- plus $998 from 25 others
Across 3 payments — averaging $8246.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$17K
- Acadia Pharmaceuticals Inc$8K
What the payments were for
- Consulting fees$11,20012%
- Speaking & faculty fees$74,47377%
- Travel & lodging$5,9806%
- Food & beverage$3,8304%
- Education$1,4221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 91 | $88,069 |
| Livanova USA, Inc. | 6 | $2,520 |
| Medtronic(2 entities) | 12 | $2,290 |
| Amneal Pharmaceuticals LLC | 4 | $1,381 |
| Boston Scientific | 10 | $1,351 |
| AbbVie(2 entities) | 17 | $296 |
| Teva Pharmaceuticals USA, Inc. | 3 | $116 |
| Genentech USA, Inc. | 5 | $108 |
| Eisai Inc. | 4 | $84 |
| Abbott | 5 | $79 |
| Kyowa Kirin, Inc. | 4 | $76 |
| Merz North America, Inc. | 2 | $49 |
| Lundbeck LLC | 3 | $47 |
| Novartis | 3 | $44 |
| SK Life Science, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Merz Pharmaceuticals, LLC | 2 | $33 |
| Bristol Myers Squibb | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Neurelis, Inc. | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| MDD US Operations, LLC | 1 | $18 |
| Pfizer | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$75,424
- ONGENTYS$10,895
- VNS Therapy$2,520
- ACTIVA$1,879
- GENERAL DBS$1,168
- ONGENTYS 50MG CAPSULES 30$890
How this compares
$96,906 in reported general payments places this provider in the 95th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $213,546 |
| IngrezzaValbenazine Tosylate | 17 | $138,599 |
| GocovriAmantadine Hcl | 31 | $111,329 |
| Austedo XrDeutetrabenazine | 20 | $103,201 |
| AustedoDeutetrabenazine | 15 | $99,552 |
| NuplazidPimavanserin Tartrate | 11 | $56,185 |
| RytaryCarbidopa/Levodopa | 22 | $25,182 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 874 | $25,055 |
| OngentysOpicapone | 18 | $18,937 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 264 | $14,632 |
| Entacapone | 52 | $9,340 |
| Propranolol Hcl ErPropranolol Hcl | 166 | $7,598 |
| EliquisApixaban | 12 | $6,693 |
| AmantadineAmantadine Hcl | 157 | $6,329 |
| LyricaPregabalin | 12 | $5,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $116 | $202,75335 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $88,069 | $157,53735 claims |
| MDD US Operations, LLCGocovri | $18 | $111,32931 claims |
| Acadia Pharmaceuticals IncNuplazid | $14 | $56,18511 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $1,381 | $25,77939 claims |
| PfizerEliquis, Lyrica | $16 | $12,00324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 neurology providers in South Dakota.
Other neurology in Sioux Falls
- Wijdan RaiSioux Falls$81K
- Jeffrey BoyleSioux Falls$14K
- Mehwish FarooqiSioux Falls$12K
- Bassel SalemSioux Falls$7K
- Cynthia Zevallos MauSioux Falls$6K
- Karan TopiwalaSioux Falls$4K
- Jorge SanchezSioux Falls$3K
- Nessim AminSioux Falls$1K
- Lisa ViolaSioux Falls$1K
- Xi WangSioux Falls$982
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.